Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
Номер патента: EP4422747A1
Опубликовано: 04-09-2024
Автор(ы): Emmanuel DEAU, Frédéric MIEGE, Laurent Meijer, Pascal George, Sylvie ARCHAMBAUD
Принадлежит: Perha Pharmaceuticals
Опубликовано: 04-09-2024
Автор(ы): Emmanuel DEAU, Frédéric MIEGE, Laurent Meijer, Pascal George, Sylvie ARCHAMBAUD
Принадлежит: Perha Pharmaceuticals
Реферат: The present invention relates to a compound of formula (I) wherein A, B, C, D and E are selected from the group consisting of =CH- and -N=, R 2 is selected from a hydrogen atom, a (C 1 -C 4 )alkyl group and a (C 3 -C 6 )cycloalkyl group, R 1 represents a (C 4 -C 6 )alkyl group, a (C 3 -C 8 )cycloalkyl group, a bridged (C 6 -C 10 )cycloalkyl group, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C 1 -C 3 )alkanediyl group, and R' represents, a (C 3 -C 8 )heterocycloalkyl group, or a (C 3 -C 8 )heteroaryl group, or a R'-L- group wherein L is a (C 1 -C 3 )alkanediyl group, and R' is a an optionally substituted phenyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits and neuroinflammation associated with Down syndrome, Alzheimer's disease, dementia and/or tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; tendinopathy and osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia, infections and for regulating body temperature.
Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
Номер патента: CA3236134A1. Автор: Laurent Meijer,Emmanuel DEAU,Pascal George,Frédéric MIEGE,Sylvie ARCHAMBAUD. Владелец: Perha Pharmaceuticals. Дата публикации: 2023-05-04.